Neurogene NGNE
$25.31 −$0.34 (-1.33%)
Market closed · Nov 6, 8:20 pm ET · Last extended-hours $25.31 0.00%
Open$26.33
Prev close$25.65
Day range$24.68 – $27.26
Volume324.9K
Market cap$506.49M
P/E (TTM)–
Dividend yield–
NGNE Stock News
Headlines matching Neurogene or the NGNE ticker, most recent first.
- Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
- H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $65 Negative
- CCORF Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $166 Negative
- A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $63 to $166
- LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $65 Positive
- LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
- H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $70
- William Blair Maintains Neurogene(NGNE.US) With Buy Rating
- Guggenheim Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $69
- A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $60 to $180
- Rodman & Renshaw Initiates Neurogene(NGNE.US) With Buy Rating, Announces Target Price $70
- LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $60
- Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE)
- Craig-Hallum Maintains Neurogene(NGNE.US) With Buy Rating, Announces Target Price $65
- CCORF Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $180
No comments yet — be the first to weigh in on NGNE.
Sign in to join the discussion.